These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471 [TBL] [Abstract][Full Text] [Related]
7. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202 [TBL] [Abstract][Full Text] [Related]
8. Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls. Paris J; Zweig-Frank H; Kin NM; Schwartz G; Steiger H; Nair NP Psychiatry Res; 2004 Jan; 121(3):239-52. PubMed ID: 14675743 [TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Anand A; Charney DS; Delgado PL; McDougle CJ; Heninger GR; Price LH Am J Psychiatry; 1994 Nov; 151(11):1626-30. PubMed ID: 7943451 [TBL] [Abstract][Full Text] [Related]
10. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Rinne T; Westenberg HG; den Boer JA; van den Brink W Biol Psychiatry; 2000 Mar; 47(6):548-56. PubMed ID: 10715361 [TBL] [Abstract][Full Text] [Related]
11. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Moss HB; Yao JK; Panzak GL Biol Psychiatry; 1990 Aug; 28(4):325-38. PubMed ID: 2397249 [TBL] [Abstract][Full Text] [Related]
12. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816 [TBL] [Abstract][Full Text] [Related]
13. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics. Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C Alcohol Clin Exp Res; 1997 Apr; 21(2):220-6. PubMed ID: 9113256 [TBL] [Abstract][Full Text] [Related]
14. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa. Levitan RD; Kaplan AS; Joffe RT; Levitt AJ; Brown GM Arch Gen Psychiatry; 1997 Jun; 54(6):521-7. PubMed ID: 9193192 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients. Lindenmayer JP; Adityanjee ; Vital-Herne M; Bark N; Grochowski S; Moynihan N Biol Psychiatry; 1997 Jul; 42(1):6-12. PubMed ID: 9193736 [TBL] [Abstract][Full Text] [Related]
17. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615 [TBL] [Abstract][Full Text] [Related]
18. Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. George DT; Benkelfat C; Rawlings RR; Eckardt MJ; Phillips MJ; Nutt DJ; Wynne D; Murphy DL; Linnoila M Am J Psychiatry; 1997 Jan; 154(1):81-7. PubMed ID: 8988963 [TBL] [Abstract][Full Text] [Related]
19. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. Pallanti S; Bernardi S; Quercioli L; DeCaria C; Hollander E CNS Spectr; 2006 Dec; 11(12):956-64. PubMed ID: 17146409 [TBL] [Abstract][Full Text] [Related]